Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
Status:
Completed
Trial end date:
2018-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg
once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).